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and middle-income countries
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André F. Carvalho12, John Lally11,13, Alex J. Mitchell14, James Mugisha15,16 and Christoph U. Correll17,18
Abstract
Background: In people with psychosis, physical comorbidities, including cardiovascular and metabolic diseases, are
highly prevalent and leading contributors to the premature mortality encountered. However, little is known
about physical health multimorbidity in this population or in people with subclinical psychosis and in low- and
middle-income countries (LMICs). This study explores physical health multimorbidity patterns among people with
psychosis or subclinical psychosis.
Methods: Overall, data from 242,952 individuals from 48 LMICs, recruited via the World Health Survey, were
included in this cross-sectional study. Participants were subdivided into those (1) with a lifetime diagnosis of
psychosis (“psychosis”); (2) with more than one psychotic symptom in the past 12 months, but no lifetime
diagnosis of psychosis (“subclinical psychosis”); and (3) without psychotic symptoms in the past 12 months or a
lifetime diagnosis of psychosis (“controls”). Nine operationalized somatic disorders were examined: arthritis,
angina pectoris, asthma, diabetes, chronic back pain, visual impairment, hearing problems, edentulism, and
tuberculosis. The association between psychosis and multimorbidity was assessed by multivariable logistic
regression analysis.
Results: The prevalence of multimorbidity (i.e., two or more physical health conditions) was: controls = 11.4%
(95% CI, 11.0–11.8%); subclinical psychosis = 21.8% (95% CI, 20.6–23.0%), and psychosis = 36.0% (95% CI, 32.1–40.
2%) (P < 0.0001). After adjustment for age, sex, education, country-wise wealth, and country, subclinical psychosis
and psychosis were associated with 2.20 (95% CI, 2.02–2.39) and 4.05 (95% CI, 3.25–5.04) times higher odds for
multimorbidity. Moreover, multimorbidity was increased in subclinical and established psychosis in all age ranges
(18–44, 45–64, ≥ 65 years). However, multimorbidity was most evident in younger age groups, with people aged
18–44 years with psychosis at greatest odds of physical health multimorbidity (OR = 4.68; 95% CI, 3.46–6.32).
(Continued on next page)
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Conclusions: This large multinational study demonstrates that physical health multimorbidity is increased across
the psychosis-spectrum. Most notably, the association between multimorbidity and psychosis was stronger
among younger adults, thus adding further impetus to the calls for the early intervention efforts to prevent the
burden of physical health comorbidity at later stages. Urgent public health interventions are necessary not only
for those with a psychosis diagnosis, but also for subclinical psychosis to address this considerable public health
problem.
Keywords: Psychosis, Physical health, Multimorbidity, Psychotic experiences, Metabolism
Background
There is now established evidence that people with psych-
osis experience a premature mortality gap of up to 15 years
before members of the general population [1, 2]. The over-
whelming majority of premature mortality cases is due
to physical health comorbidities, such as cardiovascular,
metabolic, and respiratory diseases [3]. Recent studies
have demonstrated that people with psychosis are at
greatly increased risk of cardiovascular disease [4], meta-
bolic syndrome [5], diabetes [6], and respiratory disease
[7], and that these risks are especially increased compared
to similarly aged healthy populations [8, 9]. In addition,
people with psychosis may be more likely to experience
other physical health conditions, such as arthritis, chronic
back pain [10], or edentulism, which may not increase the
risk of premature mortality, but which can negatively
impact quality of life, for example, via pain or social
stigmatization [11].
Despite the knowledge of the heightened risk of vari-
ous physical comorbidities, very little is known about
multimorbidity (i.e., two or more physical health comorbid-
ities) in people with psychosis. However, multimorbidity is
an important risk concept, as it has been associated with
functional decline [12], worse quality of life [13], increased
risk of premature mortality [14, 15], and increased health-
care costs [16]. In the largest study to date, people with
schizophrenia in Scotland (n = 9677) were significantly
more likely to have two physical health comorbidities
(OR = 1.37, 95% CI, 1.29–1.44) and three or more physical
health comorbidities (OR = 1.19, 95% CI, 1.12–1.27) than
general population controls [17]. Whilst helpful, the
focus in this study was on primary care records limited
to one country, and therefore the results are not easily
generalizable. Moreover, there is increasing recognition
that psychosis lies on a continuum, and that those with
psychotic symptoms without a full diagnosis (subclinical
psychosis) also experience an increased risk of various
physical comorbidities [18–20] and mortality [21]. To our
knowledge, no study has investigated multimorbidity in
those with subclinical psychosis. Understanding multimor-
bidity patterns can help identify higher risk subgroups,
which would preferentially benefit from tailored preventa-
tive and therapeutic strategies [22, 23].
Furthermore, data regarding multimorbidity in low-
and middle-income countries (LMICs) are scarce and
there is a lack of data on multimorbidity among those
with psychosis in this setting. This lacking literature repre-
sents an important research gap since increasing trends of
multimorbidity in LMICs will have considerable financial
implications over the next few decades [24]. In addition,
multimorbidity patterns in people with psychosis in the
context of LMICs may differ from those in high-income
countries. For example, the risk for cardio-metabolic
diseases may differ due to limited availability of second-
generation antipsychotics, many of which are known to
especially increase the risk for metabolic abnormalities [6,
7]. When antipsychotics are available in LMICs, first-
generation antipsychotics are commonly prescribed [25].
Particularly high-potency first generation-antipsychotics
appear to have a lower cardiometabolic risk profile than
most of the second-generation antipsychotics used in
high-income countries [26–28]. In addition, although
smoking is known to be a major risk factor for cardiovas-
cular diseases for patients with schizophrenia in developed
countries, the rate of smoking among those with schizo-
phrenia is not elevated compared to the general popula-
tion in some LMICs, where smoking rates have remained
high in the general population [29].
Given these aforementioned gaps in the literature, we
set out to assess the prevalence of physical comorbidity
and multimorbidity patterns in adults with psychosis
and sub-clinical psychosis across 48 LMICs. We hypoth-
esized that a clinically significant proportion of people
would be affected by physical multimorbidity and that
there would be a dose–response relationship with psych-
osis, such that adults with subclinical psychosis would
be in between the general population and those with
established psychotic disorders.
Methods
The World Health Survey (WHS) was a cross-sectional
study undertaken in 2002–2004 in 70 countries worldwide.
The aim of the study was to provide global comparable
population data on health and well-being among adults.
Details of the survey have been provided on the World
Health Organization (WHO) website (http://www.who.int/
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healthinfo/survey/en/) and in previous publications
[30, 31]. Briefly, single-stage random sampling and strati-
fied multi-stage random cluster sampling were conducted
in 10 and 60 countries, respectively. Stratification was
conducted by sex, age, and residential area (rural/urban).
Enumeration areas and households were also used as
stratification units in the majority of countries. Persons
aged 18 years or older with a valid home address were eli-
gible to participate. Each member of the household had
equal probability of being selected with the use of Kish ta-
bles. The data were collected in all countries using the
same standardized questionnaire with some countries
using a shorter version (mainly high-income countries).
Since the questions on psychosis were not included in the
shorter version, this meant that information on psychosis
was absent from the vast majority of high-income
countries. The questionnaire was translated into mul-
tiple languages and was back- and forward-translated
using a standard WHO protocol, and checked by lin-
guists to ensure comparability. Data collection was
conducted either by face-to-face interviews or via tele-
phone (Luxembourg and Israel) by trained interviewers
who had at least a high school-level education. The in-
terviewers attended a week-long course and conducted
practice field interviews prior to the actual survey. The
individual response rate across all countries was 98.5%
[32]. Ethical approval to conduct this survey was ob-
tained from ethical boards at each study site. Sampling
weights were generated to adjust for non-response and
the population distribution reported by the United Nations
Statistical Division. Informed consent was obtained from all
participants.
The current study used data from 69 countries that
have been made publically available. The data were na-
tionally representative in all countries with the exception
of China, Comoros, the Republic of Congo, Ivory Coast,
India, and Russia. Countries without any sampling in-
formation (10 countries – Austria, Belgium, Denmark,
Germany, Greece, Guatemala, Italy, Netherlands, Slovenia,
and UK) were not included in the analysis. Of the
remaining 59 countries, nine (Finland, France, Ireland,
Israel, Luxembourg, Norway, Portugal, Sweden, and
Turkey) were subsequently excluded due to missing
information on psychosis. Furthermore, the two
remaining high-income countries (Spain and United
Arab Emirates) were also excluded. Thus, the final
sample included 48 countries (21 low-income and 27
middle-income countries based on the World Bank
classification in 2003).
Physical health conditions
A total of nine physical conditions were assessed, repre-
senting all physical conditions available in the WHS.
Arthritis, asthma, and diabetes mellitus were based on
self-reported lifetime diagnosis. For angina pectoris, in
addition to a self-reported diagnosis, a symptom-based
diagnosis based on the Rose questionnaire was also
used [33]. Chronic back pain was defined as having
had back pain (including disc problems) everyday dur-
ing the last 30 days. Visual impairment was defined as
having extreme difficulty in seeing and recognizing a
person that the participant knows across the road (i.e.,
from a distance about 20 meters) [34]. A validity study
showed that this response likely corresponds to WHO
definitions of visual impairment (20/60 or 0.48 log-
MAR) [34]. The participant was considered to have
hearing problems if the interviewer observed this condi-
tion at the end of the survey. Edentulism was assessed by
the question “Have you lost all your natural teeth?” Those
who responded affirmatively were considered to have
edentulism. Finally, a tuberculosis diagnosis was based on
past 12-month symptoms and was defined as (1) having
had a cough that lasted for three weeks or longer; and
(2) having had blood in phlegm or coughed up blood
[35]. We calculated the total number of these condi-
tions while allowing for one missing variable in order
to retain a larger sample size. Multimorbidity was defined
as having at least two conditions, in line with previously
used definitions [24].
Psychosis diagnosis and psychotic symptoms
Participants were asked whether they had ever received
a diagnosis of schizophrenia or psychosis. All participants,
regardless of a psychosis diagnosis, were asked questions
on positive psychotic symptoms which came from the
WHO Composite International Diagnostic Interview
(CIDI) 3.0 [36]. This psychosis module has been reported
to be highly consistent with clinician ratings [37]. The hal-
lucinations question excluded conditions associated with
sleep-related states or substance use. Specifically, respon-
dents were asked the following questions with answer op-
tions ‘yes’ or ‘no’: During the last 12 months, have you
experienced (1) ‘A feeling something strange and unex-
plainable was going on that other people would find hard
to believe?’ (delusional mood); (2) ‘A feeling that people
were too interested in you or there was a plot to harm
you?’ (delusions of reference and persecution); (3) ‘A feel-
ing that your thoughts were being directly interfered or
controlled by another person, or your mind was being
taken over by strange forces?’ (delusions of control); (4)
‘An experience of seeing visions or hearing voices that
others could not see or hear when you were not half
asleep, dreaming or under the influence of alcohol or
drugs?’ (hallucinations).
Individuals who endorsed at least one of the four
abovementioned psychotic symptoms were considered
to have psychotic symptoms. Based on information on
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psychosis diagnosis and psychotic symptoms, a three-
category psychosis variable was constructed: (1) no
psychosis diagnosis and no psychotic symptoms (control
group); (2) at least one psychotic symptom but no
psychosis diagnosis (subclinical psychosis group); and (3)
psychosis diagnosis (psychosis group).
Other variables
Information was also examined on age, sex, country-
wise wealth, and education. Principal component ana-
lysis based on 15–20 assets was conducted to establish
country-wise wealth quintiles. Specifically, based on in-
formation on whether the participant owns items, such
as a bicycle, refrigerator, washing machine, computer,
etc., we calculated a wealth score for each individual by
weighting each asset by the coefficient of the first princi-
pal component [38]. Education (highest level achieved)
was categorized as no formal education, primary education,
secondary or high school completed, or tertiary education
completed.
Statistical analysis
The statistical analysis was performed with Stata 14.1
(Stata Corp LP, College station, Texas). Descriptive ana-
lysis was conducted to characterize the study sample
using weighted means (± standard deviations (SDs)),
proportions, and unweighted Ns. The difference in sam-
ple characteristics by the presence of multimorbidity or
psychosis was tested by χ2 tests and Student’s t-tests (or
one way ANOVA) for categorical and continuous vari-
ables, respectively. Tetrachoric correlations, which assess
the relationship between each pair of physical health
conditions (as multimorbidity was defined as having at
least two physical health conditions), were calculated for
those with subclinical psychosis or a psychosis diagnosis.
Multivariable logistic regression analysis was performed
to assess the association between psychosis (independent
variable) and multimorbidity (dependent variable),
adjusting for age, sex, education, wealth, and country.
Analyses stratified by country-income level (low-income
or middle-income countries) and age groups (18–44,
45–64, ≥ 65 years) were also conducted. Adjustment
for country was performed by including dummy vari-
ables in the models, as in previous WHS publications
[32, 39]. The sample weighting and the complex study
design were taken into account in the analyses. Results
from the logistic regression models are presented as
odds ratios (ORs) with 95% confidence intervals (CIs).
The level of statistical significance was set at P < 0.05.
Results
Data on 242,952 individuals from 48 countries were
available for the current study. Data on psychosis and
number of physical medical conditions were missing
from 12.5% and 13.9%, respectively. Details on the sam-
ple characteristics are provided in Table 1. The mean
(SD) age of the sample was 38.4 (16.0) years, and 50.6%
were female. The prevalence of subclinical psychosis and
psychosis diagnosis were 13.8% and 1.1%, respectively,
while that of multimorbidity (i.e., two or more physical
health conditions) was 13.2%.
Those with multimorbidity were significantly more
likely to be older, of female sex, and lower socioeconomic
status. The prevalence of physical health conditions is
shown in Table 2. Overall, angina pectoris (14.9%), arth-
ritis (13.2%), and chronic back pain (6.7%) were the most
common conditions. For all conditions, there was a grad-
ual increase in the prevalence from control, to subclinical
psychosis, and to psychosis diagnosis. The prevalence
of multimorbidity for control, subclinical psychosis,
and psychosis diagnosis were 11.4%, 21.8%, and 36.0%,
respectively (P < 0.0001). The prevalence of psychosis
by the different frequencies of physical health condi-
tions is illustrated in Fig. 1. A linear increase in the
prevalence of subclinical psychosis and psychosis diag-
nosis with increasing number of comorbid physical
health conditions was observed.
A significant positive correlation was observed for the
majority of the pairs of physical health conditions among
those with subclinical psychosis or psychosis diagnosis
(Table 3). For those with subclinical psychosis, the stron-
gest associations were observed for hearing problems
co-occurring with visual impairment or edentulism and
for arthritis co-existing with chronic back pain or an-
gina. For those with a psychosis diagnosis, the strongest
associations were observed for hearing problems co-
occurring with visual impairment or edentulism, asthma
co-existing with diabetes or angina or tuberculosis, and
arthritis co-existing with angina. The association be-
tween psychosis and multimorbidity assessed by multi-
variable logistic regression is presented in Table 4.
Overall, subclinical psychosis and psychosis diagnosis
were associated with 2.20 (95% CI, 2.02–2.39) and 4.05
(95% CI, 3.25–5.04) times higher odds for multimorbid-
ity. Associations in low-income and middle-income
countries were similar. However, this association was
stronger in the youngest age group (e.g., psychosis 18–
44 years; OR = 4.68; 95% CI, 3.46–6.32) with gradual
decreases in the odds being observed in the older age
groups (i.e., 45–64 years and ≥ 65 years).
Discussion
Physical health comorbidities are a major problem for
people suffering from psychotic disorders [7, 22, 40, 41].
However, to date, multimorbidity in subclinical or
clinical psychosis has received little attention. To the
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best of our knowledge, the current study presents the
first multinational community-based data investigating
the association of psychosis and subclinical psychosis
with physical health multimorbidity. The main find-
ings of this study are that both subclinical psychosis
and, even more so, a diagnosis of psychosis were asso-
ciated with an increased odds for physical health mul-
timorbidity. Specifically, subclinical psychosis was
associated with a two-fold risk of multimorbidity and
those with a diagnosis of psychosis were at a four
times increased risk compared to those without any
psychosis. Moreover, we observed a linear increase in
the prevalence of subclinical psychosis and psychosis
diagnosis with an increasing number of medical condi-
tions, suggesting a close association between the num-
ber of diseases and psychosis/subclinical psychosis.
The increased multimorbidity risk was evident in both
low-income and middle-income countries. Of particu-
lar concern, the association between psychosis and
multimorbidity was strongest in the younger age pop-
ulations. Given that physical health multimorbidity
can greatly increase the risk of mortality [15] and
healthcare costs [16], our results confirm the considerable
health strain evident among the psychosis spectrum,
underscoring the fact that early intervention and pre-
vention of both psychosis and physical health morbid-
ities are key [22, 28, 42].
Interestingly, whilst our data found that all age ranges
of people with psychosis and subclinical psychosis are
at increased odds of experiencing physical health mul-
timorbidity, people aged between 18–44 were at par-
ticular risk. Antipsychotic use, smoking and sedentary
lifestyle have been suggested to be the main contributors
to the increased risk of cardiometabolic diseases in
schizophrenia [5, 43–45]. More recently, there has been
increasing concern about the poor dietary intake and,
in particular, excess consumption of saturated fats,
sugar, and low fiber intake, which can increase the risk
of cardiometabolic disease [46]. The increased risk for
diseases such as angina pectoris and diabetes observed
in subclinical psychosis may also be associated with
similar risk factors seen in schizophrenia since smoking
and eating problems are also highly prevalent in sub-
clinical psychosis [29, 47], although it is unlikely that
Table 1 Characteristics of the sample (overall and by presence of multimorbidity)
Multimorbidity
Total No Yes
Characteristic Unweighted N Unweighted N Unweighted N
Psychosis category
Control 179,429 85.1 160,143 86.8 19,286 74.1
Subclinical psychosisa 25,493 13.8 19,883 12.4 5610 22.9
Psychosis diagnosisb 2224 1.1 1502 0.8 722 2.9
Sex
Male 93,358 49.4 84,268 51.2 9090 37.4
Female 115,846 50.6 98,964 48.8 16,882 62.6
Age, years (Mean (SD)) 38.4 (16.0) 36.1 (14.5) 53.5 (16.8)
Education
No formal 48,343 26.4 39,043 24.5 9300 39.2
Primary 71,356 31.4 62,449 31.5 8907 31.0
Secondary completed 72,087 32.7 66,072 34.3 6015 22.4
Tertiary completed 17,287 9.5 15,564 9.8 1723 7.4
Wealth (quintiles)
Poorest 47,582 20.3 40,246 19.5 7336 25.5
Poorer 41,449 20.0 35,989 19.7 5460 21.9
Middle 37,705 19.8 33,350 20.0 4355 19.0
Richer 35,378 19.9 31,597 20.3 3781 17.2
Richest 33,305 19.9 30,111 20.5 3194 16.3
Data are percentages unless otherwise stated
aSubclinical psychosis refers to having at least one of delusional mood, delusions of reference and persecution, delusions of control, and hallucinations in the past
12 months but without a psychosis diagnosis
bPsychosis diagnosis refers to self-reported lifetime diagnosis of schizophrenia/psychosis
The differences in all sample characteristics between those with and without multimorbidity were statistically significant (P < 0.0001)
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antipsychotics are commonly prescribed in this condi-
tion. Smoking, in particular, may increase the risk for
multiple physical comorbidities in psychosis as it has
also been associated with non-cardiometabolic diseases
such as tuberculosis, edentulism, and asthma [48–50]. Fi-
nally, psychological distress arising from multiple physical
health conditions may also be implicated in the increased
risk for subclinical psychosis [51]. The finding that the as-
sociation between multimorbidity and psychosis was
stronger among the younger adds further impetus to the
calls for the early intervention efforts to prevent the bur-
den of physical health comorbidity at later stages [52].
Table 2 Prevalence of physical health conditions by psychosis category
Physical health condition Total (a) Control (b) Subclinical
psychosisa
(c) Psychosis
diagnosisb
Overall
P value
P value (a)
vs. (b)
P value (a)
vs. (c)
P value (b)
vs. (c)
Tuberculosis 1.7 1.3 3.7 7.0 <0.0001 <0.0001 <0.0001 0.0009
Visual impairment 1.3 1.2 2.0 3.8 <0.0001 <0.0001 <0.0001 <0.0001
Hearing problem 3.3 3.2 3.6 8.1 <0.0001 0.1045 <0.0001 <0.0001
Chronic back pain 6.7 5.7 11.7 15.0 <0.0001 <0.0001 <0.0001 0.0182
Edentulism 5.9 5.7 7.4 9.0 <0.0001 <0.0001 0.0011 0.1837
Arthritis 13.2 12.1 18.2 30.5 <0.0001 <0.0001 <0.0001 <0.0001
Angina pectoris 14.9 13.1 24.8 33.0 <0.0001 <0.0001 <0.0001 <0.0001
Asthma 5.1 4.5 8.5 14.8 <0.0001 <0.0001 <0.0001 <0.0001
Diabetes mellitus 3.0 2.6 5.0 6.5 <0.0001 <0.0001 <0.0001 0.0689
Number of physical health conditions
Mean number (SD) 0.55 (0.90) 0.49 (0.86) 0.83 (0.99) 1.27 (1.33) <0.0001 <0.0001 <0.0001 <0.0001
0 65.2 68.0 49.6 37.5 <0.0001 <0.0001 <0.0001 <0.0001
1 21.8 20.6 28.6 26.5
2 8.6 7.5 14.1 17.8
3 3.2 2.7 5.2 10.9
4 1.1 0.9 1.9 5.1
≥ 5 0.3 0.3 0.6 2.3
Data are column percentage (i.e., the prevalence of each physical health condition among those in that psychosis category) or mean (SD). Estimates are based on
weighted sample
aSubclinical psychosis refers to having at least one of delusional mood, delusions of reference and persecution, delusions of control, and hallucinations in the past
12 months but without a psychosis diagnosis
bPsychosis diagnosis refers to self-reported lifetime diagnosis of schizophrenia/psychosis
Fig. 1 Prevalence of psychosis by number of physical health conditions. Subclinical psychosis referred to having at least one of delusional mood,
delusions of reference and persecution, delusions of control, and hallucinations in the past 12 months but without a psychosis diagnosis. Psychosis
diagnosis refers to self-reported lifetime diagnosis of schizophrenia/psychosis
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Across the entire sample of people from LMICs, we
found evidence that better education status and wealth
were both protective factors for physical multimorbidity.
Literature in the general population has similarly found
that wealth and higher education are protective factors
for better health outcomes, including mortality and
physical multimorbidity [53]. The reason for this pro-
tective relationship might be an increased awareness
of health risks in higher educated people, while those
with a better socioeconomic status have better health
coverage or greater means to access and obtain health-
care than those with less means, in particular in
LMICs [54].
This study demonstrates that physical multimorbidity
is a very real problem across the psychosis spectrum in
LMICs. Strategies to deal with this important issue are
urgently needed, particularly targeting the earlier stage
of psychotic illness. For example, relevant steps towards
adequately addressing multimorbidity that have been
underlined before include integrating physical multimor-
bidity into clinical guidelines; routinely providing self-care
management strategies, including advice on a healthy and
active lifestyle; prioritizing the prevention of chronic con-
ditions; and avoiding fragmented care [22, 40, 41, 53, 55].
Existing healthcare models need to be adapted to the in-
creasing multimorbidity rates, which will need to include
coordination with physical healthcare providers due to
increasingly complex presentations. The adaptation of
existing healthcare systems is especially relevant in
LMICs, where all levels of care must be carefully planned
in the context of economic restraints. The Innovative
Care for Chronic Conditions framework developed by
WHO provides an initial roadmap to cope with chronic
conditions in developing countries, but there still is a
need to fully incorporate physical multimorbidity
within primary and mental healthcare settings [56].
First of all, there is a clear need to increase awareness
of the importance of physical health needs of people
with psychosis among primary and mental healthcare
providers in LMICs. Continued medical education (a
common practice in LMICs [57]) should be used to in-
form health providers about the importance of asses-
sing physical health risks in people with psychosis.
Health providers in LMICs need to be informed that
their roles extend beyond taking care of the mental
health of their patients and assume responsibility for
both the mental and physical health of their patients
[57]. There is also the need for mental health education
institutions that train medical personnel to include
physical health screening/monitoring as part of their
curriculum. Policymakers should be made aware that
investment in continued medical education and in the
Table 3 Tetrachoric correlations of physical health conditions in subclinical psychosis and psychosis diagnosis
Tuberculosis Visual impairment Hearing problem Chronic back pain Edentulism Arthritis Angina Asthma Diabetes
Subclinical psychosis
Tuberculosis 1
Visual impairment 0.0343 1
Hearing problem 0.1030* 0.3313* 1
Chronic back pain 0.1469* 0.2638* 0.1986* 1
Edentulism 0.0061 0.2515* 0.3388* 0.1524* 1
Arthritis 0.1808* 0.2033* 0.2685* 0.3180* 0.2017* 1
Angina pectoris 0.2118* 0.1573* 0.1488* 0.2290* 0.1204* 0.3190* 1
Asthma 0.2126* 0.1025* 0.1133* 0.1021* 0.1168* 0.1460* 0.2270* 1
Diabetes mellitus 0.0773* 0.1850* 0.1422* 0.1224* 0.2823* 0.2222* 0.1966* 0.1709* 1
Psychosis diagnosis
Tuberculosis 1
Visual impairment 0.156 1
Hearing problem 0.1201 0.3096* 1
Chronic back pain 0.1053 0.098 0.2158* 1
Edentulism 0.0546 0.114 0.3460* 0.0692 1
Arthritis 0.1855* 0.2364* 0.2079* 0.2897* 0.1464* 1
Angina pectoris 0.2844* 0.1076 0.1277* 0.1586* 0.1922* 0.3748* 1
Asthma 0.3908* 0.1904* 0.1224 0.1290* −0.0394 0.2360* 0.3210* 1
Diabetes mellitus 0.2576* 0.2472* 0.1418 0.0826 0.1362 0.2136* 0.2788* 0.3674* 1
*P < 0.05
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Table 4 Association between psychosis and multimorbidity (outcome) estimated by multivariable logistic regression analysis
Total Low-income countries Middle-income countries Age 18–44 years Age 45–64 years Age≥ 65 years
Characteristic OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Psychosis category
Control 1.00 1.00 1.00 1.00 1.00 1.00
Subclinical psychosisa 2.20*** (2.02–2.39) 2.03*** (1.80–2.28) 2.43*** (2.16–2.74) 2.71*** (2.40–3.05) 1.93*** (1.68–2.20) 1.69*** (1.40–2.04)
Psychosis diagnosisb 4.05*** (3.25–5.04) 3.99*** (3.00–5.31) 4.07*** (2.93–5.65) 4.68*** (3.46–6.32) 3.78*** (2.77–5.16) 2.22** (1.34–3.68)
Sex
Male 1.00 1.00 1.00 1.00 1.00 1.00
Female 1.66*** (1.56–1.77) 1.59*** (1.45–1.74) 1.74*** (1.59–1.89) 1.70*** (1.55–1.88) 1.77*** (1.60–1.96) 1.39*** (1.21–1.59)
Age, years 1.07*** (1.06–1.07) 1.06*** (1.06–1.06) 1.07*** (1.07–1.08) 1.07*** (1.06–1.07) 1.07*** (1.06–1.08) 1.06*** (1.05–1.07)
Education
No formal 1.00 1.00 1.00 1.00 1.00 1.00
Primary 0.97 (0.88–1.07) 0.99 (0.88–1.12) 0.85* (0.74–0.99) 0.98 (0.85–1.13) 0.95 (0.82–1.11) 0.81* (0.67–0.99)
Secondary completed 0.72*** (0.64–0.82) 0.71*** (0.60–0.85) 0.68*** (0.57–0.82) 0.74*** (0.62–0.88) 0.64*** (0.52–0.79) 0.76* (0.58–0.99)
Tertiary completed 0.61*** (0.51–0.74) 0.54** (0.35–0.83) 0.61*** (0.50–0.74) 0.62* (0.43–0.90) 0.59*** (0.46–0.75) 0.66* (0.48–0.91)
Wealth (quintiles)
Poorest 1.00 1.00 1.00 1.00 1.00 1.00
Poorer 0.92 (0.83–1.01) 0.94 (0.81–1.07) 0.90 (0.80–1.02) 0.91 (0.79–1.05) 0.97 (0.84–1.12) 0.82* (0.68–1.00)
Middle 0.83*** (0.76–0.92) 0.82** (0.71–0.93) 0.87* (0.76–0.99) 0.79** (0.69–0.91) 0.86* (0.73–1.00) 0.92 (0.75–1.13)
Richer 0.84*** (0.76–0.92) 0.85* (0.74–0.98) 0.84** (0.74–0.96) 0.80** (0.69–0.92) 0.90 (0.78–1.05) 0.89 (0.72–1.09)
Richest 0.85** (0.76–0.96) 0.90 (0.77–1.05) 0.83* (0.70–0.98) 0.79* (0.67–0.95) 0.97 (0.81–1.15) 0.88 (0.69–1.12)
OR odds ratio, CI confidence interval
Models are adjusted for all covariates in the respective columns and country
aSubclinical psychosis refers to having at least one of delusional mood, delusions of reference and persecution, delusions of control, and hallucinations in the past 12 months but without a psychosis diagnosis
bPsychosis diagnosis refers to self-reported lifetime diagnosis of schizophrenia/psychosis
*P < 0.05, **P < 0.01, ***P < 0.001
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screening for physical health risks is likely to optimize
mental and physical health outcomes. However, effective
monitoring of metabolic risks is not sufficient on its own,
as appropriate treatment is also mandatory [5, 58]. Finally,
evidence indicates that the treatment of somatic diseases
is often neglected in populations with psychotic disorders
compared to non-psychotic healthcare users [40, 41].
For example, routine medical appointments are sched-
uled less often and medications for cardio-metabolic
conditions [59–63] are sub-optimally prescribed when
patients with psychosis are compared to those who are
non-psychotic.
Limitations
The current findings should be interpreted in light of some
study limitations. First, the study was cross-sectional, there-
fore cause and effect cannot be deduced with certainty.
Nonetheless, regardless of directionality, this survey
provides a clear public health message. In addition, the
diagnosis of psychosis was not assessed by a clinical
interview. Moreover, the self-report measure may have
led to a bias in the diagnosis of the medical conditions,
particularly in older subjects. However, this potential
bias would have been the same across all three com-
pared groups, so that the observed gradient remains
meaningful. In addition, the dataset only covered nine
major physical comorbidities. Therefore, other physical
health comorbidities may well have been evident but
not identified in the dataset. Future research should
consider additional cardiometabolic conditions, such as
hypertension and stroke, which were missing from the
evaluated questionnaires. Furthermore, although multi-
morbidity, defined by two or more physical conditions,
has a relevant impact on morbidity, functioning, quality
of life, and mortality [12–16], we recognize that specific
physical illnesses are different regarding their severity
and impact on these outcomes. In addition, due to
poor/incomplete data, we were not able to investigate
the impact of smoking, substance use, and medication
on the relationship between psychosis and multimorbidity.
Future research should attempt to assess the degree to
which these factors contribute to this relationship. Next,
future research should seek to explore the relationship
between psychosis and multimorbidity in high-income
countries as there may be contextual differences com-
pared with LMICs. For example, as has been reported
previously [32], our LMIC sample had a higher preva-
lence of subclinical psychosis than generally reported
figures from high-income countries. Moreover, the
sample is based on community dwelling people,
whereas other groups of people with psychosis (e.g., in-
patients) may have poorer physical health; the study
does not account for this at-risk group. Finally, the
reliance on self-report and not medical records may
mean that our data are actually underestimates. Despite
these limitations, the strengths of the study include a
large sample size and the multi-national scope, includ-
ing most regions of the world, but in particular under-
studied LMICs in Africa, Latin-America, Asia, and
Eastern Europe.
Conclusions
In conclusion, people with psychosis and subclinical
psychosis in LMICs had a higher risk for multiple phys-
ical conditions. Given that levels of stigma attached to
mental disorders may be high in this setting [64], and
treatment for both mental disorders and physical health
conditions are often suboptimal in LMICs, physical
multimorbidity may be associated with a particularly
devastating consequence for those with psychosis in
this setting. Future studies are needed to assess the im-
pact and cost-effectiveness of global preventive and
therapeutic strategies targeting physical multimorbidity
in individuals across the full psychotic spectrum.
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